The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide.
The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide.
复制标题
与拉坦前列素、噻吗洛尔和多佐胺联合治疗时，用布林佐胺替代多佐胺的疗效和眼部不适。
DOI：
10.1089/jop.2005.21.395
复制
发表时间：
2005
影响因子：
2.3
通讯作者：
H. Mishima
中科院分区：
文献类型：
--
作者：
H. Tsukamoto;H. Noma;S. Mukai;H. Ikeda;H. Mishima
目的
本研究的目的是评估用布林佐胺替代多佐胺治疗接受拉坦前列素、噻吗洛尔和多佐胺治疗的青光眼患者的疗效和眼部不适。
方法
对 58 名接受拉坦前列素、噻吗洛尔和多佐胺治疗的原发性开角型青光眼患者进行了一项为期 8 周的前瞻性、随机、开放标签比较研究。这些患者被随机分为两组：（1）每日3次多佐胺改为每日2次布林佐胺（替代组）； (2)继续每日3次多佐胺(对照组)。在入组后的基线、4 周和 8 周测量眼压 (IOP)。在访谈中记录了患者在滴注时的主观眼部不适（刺激和视力模糊）。
结果
基线、入组后第 4 周和第 8 周时，替代组的眼压分别为 17.7 +/- 2.7 mmHg、17.5 +/- 2.6 mmHg 和 17.4 +/- 2.9 mmHg，而替代组的眼压分别为 18.0 +/- 2.5 mmHg、17.8 +/- 2.5 mmHg 和 17.9 +/- 2.6 mmHg。分别为对照组。两组眼压变化无显着差异（P = 0.74）。在替代组中，眼部刺激显着降低（P = 0.0014），从 63% 降至 20%。替代组中视力模糊从 27% 轻微增加至 37%，但并不显着（P = 0.58）。在对照组中，眼刺激（P = 0.58，从 68% 到 57%）和视力模糊（P = 0.99，从 25% 到 21%）均没有改变。
结论
用布林佐胺替代多佐胺可维持稳定的眼压，并改善青光眼患者的眼部舒适度。
PURPOSE
The aim of this study was evaluate the efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in patients with glaucoma treated by latanoprost, timolol, and dorzolamide.
METHODS
An 8-week, prospective, randomized, open-label, comparative study was performed in 58 patients with primary open-angle glaucoma treated by latanoprost, timolol, and dorzolamide. These patients were randomly enrolled into two groups: (1) dorzolamide three times daily was substituted with brinzolamide twice-daily (substituting group); and (2) dorzolamide three times daily was continued (control group). Intraocular pressure (IOP) was measured at baseline, 4, and 8 weeks after the enrollment. Subjective ocular discomfort (irritation and blurred vision) at the time of the instillation of the patient was noted with interview.
RESULTS
The IOPs at baseline, 4 and 8 weeks after the enrollment were 17.7 +/- 2.7 mmHg, 17.5 +/- 2.6 mmHg, and 17.4 +/- 2.9 mmHg in the substituting group, and 18.0 +/- 2.5 mmHg, 17.8 +/- 2.5 mmHg, and 17.9 +/- 2.6 mmHg in the control group, respectively. There were no significant differences in IOP changes between the two groups (P = 0.74). In the substituting group, ocular irritation was decreased significantly (P = 0.0014) from 63% to 20%. The slight increase of blurred vision from 27% to 37% that occurred in the substituting group was not significant (P = 0.58). In the control group, neither ocular irritation (P = 0.58, from 68% to 57%) nor blurred vision (P = 0.99, from 25% to 21%) was changed.
CONCLUSIONS
Substituting brinzolamide for dorzolamide maintained stable IOP with improvement in ocular comfort in patients with glaucoma.